Pharmacist Information

Dispensing colchicine? Go with Mitigare®

Universal True Blue Savings Card—See Details and Download Yours Now!

Your patients can receive Mitigare® or Generic Colchicine 0.6 mg Capsules for as little as $0* for the first 30 days and get refills for as low as $5*.

Hikma offers lower-priced Brand and Generic Colchicine products for gout flare prevention.1

A few important notes for dispensing pharmacists:

  • When you receive a brand-specific Mitigare® prescription, you have the option to substitute with Authorized Generic Colchicine Capsules.

  • Mitigare® and Generic Colchicine Capsules are covered by 90% of major health plans.†

*For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are as little as $0 and refills as little as $5 only for eligible patients. Maximum savings of $65 on the first fill and $50 on refills. Review the complete Terms and Conditions and eligibility requirements.

†Managed Markets Insight & Technology, LLC database and formulary status as of January 2021.

Universal True Blue
Savings Card

DETAILS & DOWNLOAD

Mitigare®: Care Comes in a Capsule

Don’t forget to replenish your inventory of Mitigare® (Colchicine) 0.6 mg Capsules and Authorized Generic Colchicine 0.6 mg Capsules. Adults living with gout will appreciate this affordable gout flare prevention option. Available in 30-count bottles!

care comes in a capsule seal

Mitigare (Colchicine) 0.6 mg Capsules

ProductNDC#Bottle
Mitigare® 0.6 mg Capsules59467-318-3030 ct
Mitigare® 0.6 mg Capsules59467-318-01100 ct
Mitigare® 0.6 mg Capsules59467-318-101,000 ct

Authorized Generic Colchicine 0.6 mg Capsules

ProductNDC#Bottle
Colchicine 0.6 mg Capsules0143-3018-3030 ct
Colchicine 0.6 mg Capsules0143-3018-01100 ct
Colchicine 0.6 mg Capsules0143-3018-101,000 ct

How Does True Blue Savings Work?

With the Mitigare® True Blue Savings card, eligible adult patients can:

  • Receive Mitigare® (Colchicine) 0.6 mg Capsules or Generic Colchicine 0.6 mg Capsules for as little as $0* for the first 30 days and refills for as little as $5.*
  • Use the co-pay card for Mitigare® Capsules or Authorized Generic Colchicine Capsules.
  • Count on a lower Wholesale Acquisition Cost (WAC).1

*For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are as little as $0 and refills as little as $5 only for eligible patients. Maximum savings of $65 on the first fill and $50 on refills. Review the complete Terms and Conditions and eligibility requirements.

senior couple checking in at the doctor's office

Help Eligible Patients Save

With the Universal True Blue Savings Card

Now pharmacists can help their eligible customers who do not have a True Blue Savings Card get their first 30 days of Mitigare® or Authorized Generic Colchicine Capsules for as little as $0* and refills for as low as $5.*

DETAILS & DOWNLOAD

References

  1. First Databank. AnalySource® website. Available at: https://www.analysource.com/. Accessed January 6, 2020.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Read More...

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.